Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan

Journal of the Formosan Medical Association

Volumn 107, Issue 1, 2008, Pages 4-12

  Wu, Shang Ju ^a   Chen, Chien Yuan ^a   Su, Ih Jen ^b   Tang, Jih Luh ^a   Chou, Wen Chen ^a   Ko, Bo Sheng ^a   Huang, Sheng Yi ^a   Yao, Ming ^a   Tsay, Woei ^a   Chen, Yao Chang ^a   Wang, Chiu Hwa ^a   Tien, Hwei Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Hodgkin's disease; Lymphoma; Taiwan

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 39549099479     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60002-9     Document Type: Article

References (32)

1. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776-83.
2. Diehl V, Franklin J, Sextro M, et al. Clinical presentation and treatment of lymphocyte predominant Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, et al, eds. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999:563.
3. Clarke CA, Glaser SL, Keegan TH, et al. Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California, Cancer Epidemiol Biomarkers Prev 2005;14: 1441-7.
4. Glaser SL, Hsu JL. Hodgkin's disease in Asians. Incidence patterns and risk factors in population-based data. Leuk Res 2002;26:261-9.
5. Shimizu H. Tajima K, Kuroishi T et al. Geographic variation of Hodgkin's disease in Japan. Nagoya J Med Sci 1981; 43:101-10.
6. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063-83.
7. Lister TA, Crowther D. Staging for Hodgkin's disease. Semin Oncol 1990;17:696-703.
8. Blasinska-Morawiec M, Pluzanska A, Krykowski E, et al. Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone). Pol Arch Med Wewn 1991;86:274-80.
9. Morgenfeld MC, Pavlovsky A, Suarez A, et al. Combined cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. Cancer 1975;36:1241-9.
10. Bonadonna G, Santoro A, Gianni AM, et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 1991; 2:9-16.
11. Diehl V, Pfreundschuh M, Loffler M, et al. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and clacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother 1989;6:155-62.
12. Ruffer JU, Ballova V, Glossmann J, et al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkin's disease - results of the German Hodgkin Study Group. Leuk Lymphoma 2005;46:1561-7.
13. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339: 1506-14.
14. Mueller NE, Grufferman S. The epidemiology of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, et al, eds. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999:61.
15. Liang R, Choi P, Todd D, et al. Hodgkin's disease in Hong Kong Chinese. Hematol Oncol 1989;7:395-403.
16. Paulino AF, Paulino-Cabrera E, Weiss LM, et al. Hodgkin's disease in the Philippines. Mod Pathol 1996;9:115-9.
17. Zhou XG, Hamilton-Dutoit SJ, Yan QH, et al. The association between Epstein-Barr virus and Chinese Hodgkin's disease. Int J Cancer 1993;55:359-63.
18. Au WY, Gascoyne RD, Gallagher RE, et al. Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey. Ann Oncol 2004;15:626-30.
19. Stein H, Delsol G, Pileri S, et al. Classical Hodgkin's lymphoma. In: World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2001.
20. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 1991;5:983-1001.
21. Chen CY, Yao M, Tang JL, et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 2004;15:1091-6.
22. Thomas RK, Re D, Wolf J, et al. Part 1: Hodgkin's lymphoma - molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004;5:11-8.
23. Diehl V, Thomas RK, Re D. Part II. Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol 2004;5:19-26.
24. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol 2006;24:605-11.
25. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006;24:5735-41.
26. Byrne BJ, Gockerman JP. Salvage Therapy in Hodgkin's Lymphoma. Oncologist 2007;12:156-67.
27. Murphy F, Sirohi B, Cunningham D. Stem cell transplantation in Hodgkin's lymphoma. Exp Rev Anticancer Ther 2007;7:297-306.
28. Schmitz N, Sureda A. The role of allogeneic stem-cell transplantation in Hodgkin's disease. Eur J Haematol 2005;Suppl:146-9.
29. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin's lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006;12:172-83.
30. Anderlini P, Champlin RE. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: where do we stand? Biol Blood Marrow Transplant 2006;12:599-602.
31. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin's disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-14.
32. Josting A, Wolf J, Diehl V. Hodgkin's disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000; 12:403-11.